N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]phenyl}-N'-(3-nitrophenyl)urea | 190727-14-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]phenyl}-N'-(3-nitrophenyl)urea
• 英文别名: 1-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(3-nitrophenyl)urea
• CAS: 190727-14-1
• 化学式: C₂₄H₂₀N₄O₆
• 分子量: 460.446
• InChiKey: FEMXGYPLUJMECJ-UHFFFAOYSA-N

物化性质

• 熔点：
  154 °C
• 沸点：
  562.2±50.0 °C(Predicted)
• 密度：
  1.405±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]phenyl}-N'-(3-nitrophenyl)urea 在 palladium hydroxide carbon 氢气 、 Brine 、 Sodium sulfate-III 作用下， 以 N,N-dimethylformamide ethyl acetate 为溶剂， 反应 3.0h， 以to obtain 13 mg of the title compound (yield: 51%)的产率得到N-(3-Aminophenyl)-N'-{4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}urea
  参考文献：
  名称：

  Quinoline and quinazoline derivatives inhibiting platelet-derived growth

  摘要：

  本发明涉及一种新型喹啉衍生物和喹嗪衍生物，其由以下式子（I）所表示：##STR1## [其中R.sub.1和R.sub.2各自独立地为H或C.sub.1-C.sub.4-烷基，或者R.sub.1和R.sub.2共同形成C.sub.1-C.sub.3-亚烷基，X为O、S或CH.sub.2，W为CH或N，Q为取代芳基或取代杂环芳基]及其药学上可接受的盐，具有血小板源性生长因子受体自磷酸化抑制活性，以及含有这些化合物的制药组合物，以及用于治疗与异常细胞生长相关的疾病，如肿瘤的方法。

  公开号：

  US06143764A1
• 作为产物：
  描述：

  2'-氨基-4',5'-二甲氧基苯乙酮 在 palladium dihydroxide 氢气 、 sodium methylate 、 三乙胺 、 三氯氧磷 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.67h， 生成 N-{4-[(6,7-Dimethoxy-4-quinolyl)oxy]phenyl}-N'-(3-nitrophenyl)urea
  参考文献：
  名称：

  Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4-(4-quinolyloxy)phenyl}ureas

  摘要：

  N-Phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas were found to be a novel class of potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase through synthetic modifications of a lead compound and structure-activity relationship studies. A representative compound 6ab, termed Ki8751, inhibited VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibited the PDGFR family members such as PDGFR(x and c-Kit at 67 nM and 40 nM, respectively. However, 6ab did not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM. 6ab suppressed the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level. 6ab showed significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also showed complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body weight loss.

  DOI：

  10.1021/jm030427r

文献信息

• QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP0860433B1

  公开（公告）日：2002-07-03
• US6143764A
  申请人：——

  公开号：US6143764A

  公开（公告）日：2000-11-07
• Quinoline and quinazoline derivatives inhibiting platelet-derived growth
  申请人：Kirin Beer Kabushiki Kaisha

  公开号：US06143764A1

  公开（公告）日：2000-11-07

  The present invention relates to novel quinoline derivatives and quinazoline derivatives represented by the following formula (I): ##STR1## [wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.4 -alkyl, or R.sub.1 and R.sub.2 together form C.sub.1 -C.sub.3 -alkylene, X is O, S or CH.sub.2, W is CH or N, and Q is a substituted aryl group or substituted heteroaryl group] and their pharmaceutically acceptable salts, having platelet-derived growth factor receptor autophosphorylation inhibitory activity, to pharmaceutical compositions containing these compounds, and to methods for the treatment of diseases associated with abnormal cell growth such as tumors.

  本发明涉及由以下式（I）表示的新型喹啉衍生物和喹唑啉衍生物：[其中R.sub.1和R.sub.2分别独立地为H或C.sub.1 -C.sub.4 -烷基，或R.sub.1和R.sub.2一起形成C.sub.1 -C.sub.3 -烷基，X为O、S或CH.sub.2，W为CH或N，Q为取代芳基或取代杂芳基]及其在药学上可接受的盐，具有血小板源性生长因子受体自磷酸化抑制活性，用于含有这些化合物的药物组合物，以及用于治疗与异常细胞生长（如肿瘤）相关的疾病的方法。
• Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors:  Synthesis, Structure−Activity Relationships, and Antitumor Activities of <i>N</i>-Phenyl-<i>N</i>‘-{4-(4-quinolyloxy)phenyl}ureas
  作者：Kazuo Kubo、Toshiyuki Shimizu、Shin-ichi Ohyama、Hideko Murooka、Akemi Iwai、Kazuhide Nakamura、Kazumasa Hasegawa、Yoshiko Kobayashi、Noriko Takahashi、Kazumi Takahashi、Shinichiro Kato、Toshio Izawa、Toshiyuki Isoe

  DOI：10.1021/jm030427r

  日期：2005.3.1

  N-Phenyl-N'-4-(4-quinolyloxy)phenyl}ureas were found to be a novel class of potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase through synthetic modifications of a lead compound and structure-activity relationship studies. A representative compound 6ab, termed Ki8751, inhibited VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibited the PDGFR family members such as PDGFR(x and c-Kit at 67 nM and 40 nM, respectively. However, 6ab did not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM. 6ab suppressed the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level. 6ab showed significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also showed complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body weight loss.